Richard A. Jensen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Richard A. Jensen has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Ingrid Kockum
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
2 shared publications - Mona Landin-Olsson
Department of Clinical Science Lund, Lund University, SE-223 61 Lund, Sweden; Department of Endocrinology, Skane University Hospital, SE-221 85 Lund, Sweden
2 shared publications A. F. Karlsson
Institute of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden
1 shared publicationB. Lernmark
Department of Clinical Sciences, Lund University, University Hospital MAS, Malmö, Sweden and
1 shared publication- Barbro Lernmark
Department of Endocrinology, University Hospital Malmo, Malmo, Sweden
1 shared publication C. Torn
Department of Clinical Sciences, Lund University Hospital, Lund, Sweden
1 shared publication
Latest Publications
- 31 August 2007
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 21 (4) , 205-213
Multiple factors affect the loss of measurable C-peptide over 6 years in newly diagnosed 15- to 35-year-old diabetic subjects
- 31 August 2007
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 21 (4) , 205-213
Multiple factors affect the loss of measurable C-peptide over 6 years in newly diagnosed 15- to 35-year-old diabetic subjects
- 24 August 2007
- Published by Wiley in Diabetic Medicine
- Vol. 24 (11) , 1221-1228
Islet cell autoantibody levels after the diagnosis of young adult diabetic patients
Aims The aim was to determine the course of islet cell antibodies [glutamate decarboxylase (GADA), tyrosine phosphatase‐like islet antigen 2 (IA‐2A) and islet cell (ICA)] after the diagnosis of the diabetic patient. Methods The Diabetes Incidence Study in Sweden (DISS) attempted to prospectively enrol all newly diagnosed diabetic patients aged 15–34 years during 1992 and 1993. C‐peptide and autoantibody levels were determined from venous blood samples at diagnosis and again at yearly intervals for 6 years. Results After the first year, the odds of remaining GADA positive decreased by 9% per year [odds ratio (OR) = 0.91, 95% confidence interval (CI) = 0.85–0.96] while the mean GADA index remained unchanged ( = 0.8, P = 0.37). There was no change in the percentage of subjects testing IA‐2A positive after the first year ( = 0.1, P = 0.75). However, the mean index decreased 0.04 per year (95% CI: 0.03–0.05)—a 7.9% decline (95% CI: 5.4–10.4%). The odds of a subject testing positive for ICA decreased by 24% per year (OR = 0.76, 95% CI = 0.70–0.82). The mean ICA levels decreased 0.75 per year (95% CI: 0.66–0.84)—a 16.4% decline (95% CI: 14.1–18.6%). The rate of change in titres for all three autoantibodies was independent of gender, human leucocyte antigen genotype and C‐peptide status. Conclusions GADA levels remained high while ICA levels declined. In contrast to a previous study, we found that the proportion of IA‐2A subjects remaining positive did not decrease after the first year, while the average index decreased slightly.
- 24 August 2007
- Published by Wiley in Diabetic Medicine
- Vol. 24 (11) , 1221-1228
Islet cell autoantibody levels after the diagnosis of young adult diabetic patients
Aims The aim was to determine the course of islet cell antibodies [glutamate decarboxylase (GADA), tyrosine phosphatase‐like islet antigen 2 (IA‐2A) and islet cell (ICA)] after the diagnosis of the diabetic patient. Methods The Diabetes Incidence Study in Sweden (DISS) attempted to prospectively enrol all newly diagnosed diabetic patients aged 15–34 years during 1992 and 1993. C‐peptide and autoantibody levels were determined from venous blood samples at diagnosis and again at yearly intervals for 6 years. Results After the first year, the odds of remaining GADA positive decreased by 9% per year [odds ratio (OR) = 0.91, 95% confidence interval (CI) = 0.85–0.96] while the mean GADA index remained unchanged ( = 0.8, P = 0.37). There was no change in the percentage of subjects testing IA‐2A positive after the first year ( = 0.1, P = 0.75). However, the mean index decreased 0.04 per year (95% CI: 0.03–0.05)—a 7.9% decline (95% CI: 5.4–10.4%). The odds of a subject testing positive for ICA decreased by 24% per year (OR = 0.76, 95% CI = 0.70–0.82). The mean ICA levels decreased 0.75 per year (95% CI: 0.66–0.84)—a 16.4% decline (95% CI: 14.1–18.6%). The rate of change in titres for all three autoantibodies was independent of gender, human leucocyte antigen genotype and C‐peptide status. Conclusions GADA levels remained high while ICA levels declined. In contrast to a previous study, we found that the proportion of IA‐2A subjects remaining positive did not decrease after the first year, while the average index decreased slightly.